Senator Chuck Grassley continues his pursuit of questionable financial ties between the pharmaceutical companies and research by asking the National Institutes of Health (NIH) why it has awarded $400,000 for medical research to Charles Nemeroff. Nemeroff, who had been banned from NIH funding for failure to disclose a $1.2 million financial relationship with GlaxoSmithKline (the maker of Paxil) while leading a $9 million study on the treatment of depression, remains under investigation by the Inspector General for the Department of Health and Human Services. The decision to award the grant “risks sending the wrong message to physicians seeking or performing federally funded research,” Grassley said.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.